The Lung Microbiome in Sarcoidosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

21 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-06-30

Study Completion Date

2017-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to determine the presence of bacterial species, and the immunologic and molecular mechanisms of granuloma formation that might be involved in the pathogenesis of sarcoidosis. The investigators will collect peripheral blood and bronchoalveolar lavage fluid samples to isolate bacterial DNA and blood monocytes and lymphocytes. Specimens will be obtained from patients with sarcoidosis, with non-sarcoid lung disease, and healthy volunteers to directly compare the bacterial species present and the characteristics of cells thought to be involved in granuloma formation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Investigation of the Efficacy of Antibiotics on Pulmonary Sarcoidosis

NCT01169038

Pulmonary Sarcoidosis Lung Function

COMPLETED PHASE1

Trial of Antimycobacterial Therapy in Sarcoidosis

NCT01074554

Sarcoidosis

COMPLETED PHASE1/PHASE2

Prospective Evaluation of a New Molecular Tool for Early Diagnosis of Mucormycosis

NCT02845934

Mucormycosis

COMPLETED NA

the PHENOSAR Trial: Use of Antibiotics in Treatment of Sarcoidosis

NCT05291468

Sarcoidosis, Pulmonary Sarcoidosis Skin

UNKNOWN NA

A Leukapheresis Study for Immune Responses in Healthy US Adults Who Receive BCG Vaccination Followed by Boosting With AERAS-402

NCT02375256

Tuberculosis

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sarcoidosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Blood only

20 sarcoidosis subjects and 20 healthy controls will complete lifestyle questionnaires and have blood drawn for microbiome analyses.

Blood draw

Intervention Type OTHER

Questionnaires

Intervention Type BEHAVIORAL

Blood and BAL

10 sarcoidosis subjects, 10 healthy controls, and 10 subjects with non-sarcoid interstitial lung disease will complete lifestyle questionnaires and undergo blood sampling for microbiome analyses as well as bronchoscopy for bronchoalveolar lavage microbiome analyses.

Blood draw

Intervention Type OTHER

Bronchoscopy

Intervention Type PROCEDURE

Questionnaires

Intervention Type BEHAVIORAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood draw

Intervention Type OTHER

Bronchoscopy

Intervention Type PROCEDURE

Questionnaires

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical diagnosis of sarcoidosis (30 subjects) or
* Clinical diagnosis of non-sarcoid interstitial lung disease (10 subjects) or
* Age-matched controls (30 subjects)
* Ability to provide informed consent

Exclusion Criteria

* Any disease condition (such as anemia, unstable cardiac disease, etc.) that in the opinion of the subject's primary physician would put the patient at risk of harm from having 60 cc of blood drawn or for undergoing bronchoscopy for this study.
* Patients who are undergoing bronchoscopy for presumed infection.
* Pregnant women, women who may be pregnant, and women who are breastfeeding.
* Patients who have undergone lung transplantation.
* Persons who are unable or unwilling to undergo bronchoscopy, including those unable to be accompanied by a designated driver to the procedure.
* Persons who have taken antibiotics in the 90 days prior to consent.
* Known HIV, HCV, alcohol, or other substance abuse history.

Minimum Eligible Age

30 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes